An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

Exclusion criteria

• . Experienced an adverse event or serious adverse event (SAE) related to the study drug during the LUM001-301 protocol that led to the discontinuation of the participant from the core study.
• . Any conditions or abnormalities (including laboratory abnormalities) which in the opinion of the Investigator, Medical Monitor or ChiLDReN Protocol Chair, may compromise the safety of the participant, or interfere with the participant participating in or completing the study.
• . History or known presence of gallstones or kidney stones.
• . History of non-adherence during the participant's participation in the LUM001-301 protocol. Non-adherence is defined by dosing compliance (dosing compliance is calculated by \[the total number of doses that were actually taken by the participant\] divided by \[the total number of doses that should have been taken by the participant\] multiplied by 100) of less than 80% in the LUM001-301 protocol.
• . Unlikely to comply with the study protocol, or unsuitable for any other reason, as judged by the investigator.
• . All above exclusion criteria will apply upon re-entry into the long-term, optional follow-up treatment period 2.